FILTER
LATEST INTERVIEWS
Luis Osorio
EXECUTIVE DIRECTOR, PROCCYT
"Due to the regulatory backlog of approval, innovation in Mexico has paused in the past five years."
Miguel Valdivia
COMMERCIAL DIRECTOR, TRADE CHEMICALS & PRODUCTS
"Mexico is full of opportunities—there are always new factories and new clients."
Javier Constante
PRESIDENT, DOW LATIN AMERICA
"Our LatAm portfolio reflects Dow’s global capabilities, with more than 50% focused on specialty plastics for the packaging industry."
Mauricio Russomanno
CEO, UNIPAR
"By changing our energy matrix, we are also going to be reducing our energy carbon footprint by almost 10%, not to mention we will realize important savings in terms of our energy costs."
Gary Teichmann
EXECUTIVE, THE TEICHMANN GROUP
"The Teichmann Group comprises of companies with expertise in multi-disciplined construction services, mining and agriculture solutions across Southern, Central and West Africa."
Donna LaVoie
PRESIDENT AND CEO, LAVOIE HEALTH SCIENCE
"There is an insatiable demand for capital and there is too much innovation to fund."
Flor de María González
GENERAL MANAGER, ANAFAPYT
"We will continue supporting sustainable raw materials production and the development of new alternatives."
Alfredo Ison
PRESIDENT, QUÍMICA DELTA
"In the past, we diversified into the fuel market with a company called Exxia. Today, we have the new specialties company, Ion."
Gan-Ochir Zunduisuren
MANAGING DIRECTOR, ASIAN BATTERY MINERALS
"I believe Mongolia has all the potential to become an important player in the critical mineral space. The country remains broadly underexplored for these materials."
Jacob Lachapelle and Jaha Sohail
CEO-IN-TRANING (JL) AND COO (JS), MAESTRO DIGITAL MINE
"We have seen a remarkable increase in revenue, surpassing 120% YoY."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
